Can I Take Folate with Zetia (Ezetimibe)?

What Is Ezetimibe and How Does It Work?

Ezetimibe (brand name Zetia) is a lipid-lowering agent that works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestinal brush border, cutting dietary and biliary cholesterol absorption by roughly 50% without entering the systemic circulation in meaningful concentrations. The drug does not inhibit cholesterol synthesis in the liver, which is why it is frequently combined with statins.

Pharmacokinetics That Affect Supplement Interactions

After oral ingestion, ezetimibe is rapidly glucuronidated to an active metabolite (ezetimibe-glucuronide) in the intestinal wall and liver. The glucuronide undergoes enterohepatic recycling, which gives it a half-life of approximately 22 hours. Critically, ezetimibe does not meaningfully inhibit or induce CYP450 enzymes (CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4) at therapeutic doses, according to the FDA-approved prescribing information for Zetia [1]. This is a significant point: most nutrient-drug interactions occur at the CYP450 level or through transporter competition, and ezetimibe sidesteps both.

What Ezetimibe Does NOT Do

Ezetimibe does not interfere with the absorption of fat-soluble vitamins (A, D, E, K) or water-soluble vitamins, unlike bile acid sequestrants such as cholestyramine. A 2002 study published in the Journal of Clinical Pharmacology confirmed that ezetimibe 10 mg co-administered with cholestyramine 24 g/day reduced ezetimibe AUC by approximately 55%, but that effect belongs to cholestyramine, not ezetimibe itself [2]. Folate absorption is entirely unaffected by ezetimibe.

What Is Folate and Why Do People Take It?

Folate is the umbrella term for a family of water-soluble B-vitamins (B9) that serve as one-carbon donors in nucleotide synthesis and the methylation cycle. The methylation cycle converts homocysteine back to methionine. Elevated homocysteine is independently associated with increased cardiovascular risk, according to a meta-analysis of 30 prospective studies involving over 5,000 coronary heart disease events published in the BMJ [3].

People taking Zetia are, by definition, managing dyslipidemia and often carry elevated cardiovascular risk. That makes the folate-homocysteine-cardiovascular connection clinically relevant to this population, even though folate itself does not interact with ezetimibe.

Forms of Folate Available OTC

Not all folate supplements are metabolically equivalent.

• Folic acid is the synthetic oxidized form used in most generic supplements and fortified foods. It requires enzymatic reduction (DHFR) and methylation (MTHFR) before becoming active.
• 5-Methyltetrahydrofolate (5-MTHF or methylfolate) is the predominant circulating form in blood and the form directly usable by cells. Patients with MTHFR variants convert less folic acid to this active form.
• Folinic acid (leucovorin) is a reduced form used therapeutically, primarily to offset methotrexate toxicity.

For patients without MTHFR variants, standard folic acid at 400 to 800 mcg/day is adequate. For those with confirmed MTHFR C677T homozygosity, methylfolate supplementation may produce better outcomes in raising red blood cell folate and lowering homocysteine.

Recommended Dietary Allowances

The NIH Office of Dietary Supplements sets the RDA for folate at 400 mcg DFE (dietary folate equivalents) per day for adults, 600 mcg DFE during pregnancy, and 500 mcg DFE during lactation [4]. The tolerable upper intake level (UL) for folic acid from supplements and fortified foods is 1,000 mcg per day, primarily because high-dose folic acid can mask vitamin B12 deficiency.

Is There a Direct Pharmacokinetic Interaction Between Folate and Ezetimibe?

No. There is no documented pharmacokinetic interaction between folate (in any form) and ezetimibe. The two compounds do not share transporter systems at the intestinal level in a way that would cause clinically significant competition.

Absorption Pathways Are Separate

Ezetimibe is absorbed in the proximal small intestine via passive diffusion and then glucuronidated, whereas dietary and supplemental folate is absorbed primarily by the proton-coupled folate transporter (PCFT/SLC46A1) and the reduced folate carrier (RFC/SLC19A1) in the jejunum [5]. These transporters handle structurally distinct substrates. Ezetimibe, a cholesterol analogue, does not compete with folate for these carriers.

No Pharmacodynamic Antagonism

Ezetimibe lowers LDL-C by reducing intestinal cholesterol absorption. Folate lowers homocysteine by providing methyl groups through the methylation cycle. These are separate metabolic processes with no overlap. There is no evidence that one blunts the clinical effect of the other.

FDA Label Silence on Folate

The current Zetia prescribing information lists the following as clinically meaningful drug interactions: cyclosporine (increased ezetimibe exposure), bile acid sequestrants (reduced ezetimibe absorption), and fibrates (gallstone risk). Folate is not mentioned anywhere in the interaction table [1]. The absence of mention in an FDA label reviewed for safety does carry evidential weight.

MTHFR Variants: When the Conversation Gets More Nuanced

MTHFR (methylenetetrahydrofolate reductase) gene variants are common. The C677T variant reaches a homozygous frequency of 10 to 15% in North American and European populations, and the A1298C variant is also widespread. Homozygous C677T carriers have MTHFR enzyme activity reduced by approximately 70% compared to wild-type [6].

The following framework describes how clinicians at HealthRX approach folate form selection in patients on ezetimibe who also have cardiovascular risk factors or known MTHFR status.

HealthRX Folate Form Selection Framework for Patients on Ezetimibe:

| Patient Profile | Recommended Folate Form | Dose Starting Point | Monitoring | |---|---|---|---| | No MTHFR variant, no CV disease history | Folic acid | 400 mcg/day | None required | | MTHFR C677T heterozygous, no symptoms | Folic acid or methylfolate | 400 to 800 mcg/day | Annual homocysteine if at CV risk | | MTHFR C677T homozygous | Methylfolate (5-MTHF) | 400 to 1,000 mcg/day | Homocysteine at 3 months, then annually | | Elevated homocysteine (>10 micromol/L) regardless of MTHFR | Methylfolate plus B6 plus B12 | Per clinician guidance | Homocysteine recheck at 8 to 12 weeks | | Pregnancy or planning conception (on Zetia) | Discuss statins/Zetia use; if continued, methylfolate | 600 mcg DFE/day minimum | Per OB/clinician |

Why Homocysteine Matters for Zetia Patients Specifically

Patients prescribed ezetimibe typically have established dyslipidemia, metabolic syndrome, or atherosclerotic cardiovascular disease (ASCVD). Elevated homocysteine is an independent cardiovascular risk marker. The NORVIT trial (N=3,749), published in the New England Journal of Medicine, showed that B-vitamin supplementation including folic acid 0.8 mg, B12 0.4 mg, and B6 40 mg daily did not significantly reduce recurrence of cardiovascular events after acute myocardial infarction, and the high-dose B6 arm actually trended toward harm [7]. This finding does not argue against folate use at physiologic doses; it argues against megadose B-vitamin protocols in secondary prevention.

A more recent Mendelian randomization study in the BMJ (N=84,000+) confirmed that genetically predicted lower folate status is causally associated with higher homocysteine but that the downstream cardiovascular benefit of correcting this remains context-dependent [8]. The point for Zetia patients: get folate to adequacy. The evidence for supplementing beyond adequacy in cardiovascular disease is less clear.

Anticonvulsant Users Who Also Take Zetia

Anticonvulsants such as phenytoin, carbamazepine, and valproate are well-documented folate antagonists, reducing serum folate levels through mechanisms that include induction of hepatic folate metabolism and impaired intestinal absorption. Some patients may be on both an anticonvulsant and ezetimibe for comorbid epilepsy and dyslipidemia. In these cases, the indication for supplemental folate becomes stronger, but the interaction is between the anticonvulsant and folate, not between Zetia and folate. Per the American Academy of Neurology guidance, patients on chronic anticonvulsant therapy should maintain adequate folate status, with supplementation often recommended at 1 mg/day [9].

Timing: Does It Matter When You Take Folate Relative to Zetia?

No timing separation is required. Because there is no shared transporter competition or pharmacokinetic interference, folate and ezetimibe can be taken at the same time of day without concern.

Practical Dosing Notes

Ezetimibe 10 mg can be taken with or without food at any time of day. Folate supplements are similarly flexible. The only real timing consideration in the ezetimibe pharmacokinetic picture involves bile acid sequestrants: if a patient is on both cholestyramine and ezetimibe, ezetimibe should be taken either 2 hours before or 4 or more hours after the sequestrant. This is a sequestrant-ezetimibe interaction, and folate is not affected.

Methylfolate and folic acid supplements are generally better absorbed on an empty stomach or with a light meal, but this is a minor optimization, not a clinical requirement.

Monitoring Recommendations

For most patients taking ezetimibe who add a standard-dose folate supplement, no additional laboratory monitoring is needed beyond what is already indicated for their cardiovascular or lipid management.

When to Add Homocysteine Testing

Homocysteine testing may be worth ordering if a patient:

• Has confirmed MTHFR C677T homozygosity
• Has a personal or family history of premature ASCVD without fully explained traditional risk factors
• Has a serum B12 below 300 pg/mL alongside low dietary folate intake
• Is on chronic methotrexate or anticonvulsant therapy in addition to ezetimibe

A baseline plasma homocysteine level, followed by a recheck 8 to 12 weeks after starting or adjusting folate supplementation, gives enough information to confirm the supplement is working.

Lipid Panel Timing Is Unchanged

Adding folate supplementation does not interfere with ezetimibe's effect on LDL-C. The SHARP trial (N=9,270), published in The Lancet, demonstrated that ezetimibe 10 mg combined with simvastatin 20 mg reduced LDL-C by 0.85 mmol/L (approximately 33 mg/dL) compared to placebo and reduced major atherosclerotic events by 25% over 4.9 years [10]. Folate would not alter these outcomes.

What the Evidence Field Looks Like for B-Vitamins and Cardiovascular Disease

The literature on folate, B vitamins, and cardiovascular disease is large but nuanced. A 2010 Cochrane review of 8 trials (N=37,485) found that folic acid supplementation did not significantly reduce all-cause mortality, cardiovascular disease incidence, or myocardial infarction compared with placebo [11]. The HOPE-2 trial (N=5,522) did show that folic acid 2.5 mg plus B6 50 mg plus B12 1 mg daily reduced stroke risk by 25% (hazard ratio 0.75, 95% CI 0.59 to 0.97) but did not reduce the primary composite of cardiovascular death, MI, or stroke [12].

The clinical takeaway for someone on Zetia: folate at physiologic doses (400 to 800 mcg/day) is safe, reasonable for general health maintenance, and not contraindicated by ezetimibe. Going beyond 1,000 mcg/day of folic acid without clinical indication adds no documented cardiovascular benefit and risks masking B12 deficiency.

Should You Tell Your Doctor You're Taking Folate with Zetia?

Yes, and not because of the ezetimibe interaction (which is absent) but because your prescriber needs a complete supplement picture. Supplements affect overall cardiovascular risk management. Folate status interacts with homocysteine, which interacts with cardiovascular risk. If you are already on a statin plus ezetimibe and managing multiple risk factors, your clinician can use your folate and homocysteine data to optimize the full protocol.

The American College of Cardiology and American Heart Association 2019 guidelines on primary prevention of cardiovascular disease state that clinicians should assess diet, physical activity, and supplement use as part of routine cardiovascular risk evaluation [13]. Folate is specifically relevant if homocysteine elevation is identified as a residual risk factor after LDL-C is addressed.

What to Bring to Your Appointment

Bring the supplement bottle so your prescriber can see the form (folic acid vs. Methylfolate), the dose in micrograms, and any combined B-complex formulations. Some B-complex products contain 400 to 800 mcg folate plus B6 and B12 at varying doses. Your prescriber may want to check:

• Serum folate (or RBC folate, which better reflects tissue stores)
• Plasma homocysteine
• Serum B12 (because high folic acid can normalize a CBC while B12 deficiency continues)

Special Populations

Pregnant Patients on Ezetimibe

Ezetimibe is classified FDA Pregnancy Category X for combination with lovastatin (Vytorin) and is generally avoided during pregnancy due to concerns about cholesterol's role in fetal development. If a patient on Zetia becomes pregnant, the standard recommendation is to discontinue the drug immediately and consult with obstetrics. The folate requirement during pregnancy increases to 600 mcg DFE/day, and this is a maternal health priority regardless of prior ezetimibe use.

Older Adults

Adults over 65 often have reduced absorption of food-bound folate and B12. Serum B12 should be checked before starting high-dose folic acid in older patients to rule out masked pernicious anemia. Standard folate supplementation at 400 mcg/day carries minimal risk in this group and may support cognitive health as a secondary benefit.

Patients on Methotrexate for Inflammatory Conditions Plus Ezetimibe

Methotrexate is a dihydrofolate reductase inhibitor and depletes intracellular folate stores. Patients who are on low-dose methotrexate (for rheumatoid arthritis or psoriasis) and also take ezetimibe for cardiovascular risk are frequently prescribed supplemental folic acid 1 mg/day to reduce methotrexate toxicity. A Cochrane review (Shea et al., 2013, 6 trials) confirmed that folic acid or folinic acid supplementation significantly reduces gastrointestinal side effects and transaminase elevation from methotrexate without impairing its anti-inflammatory efficacy [14]. Ezetimibe plays no role in this interaction.